| Outcome Measures: |
Primary: Corrected Glucose Disposal Rate (cGDR) Measured as Change in Rate of Disposal (Delta RD) Basal vs High Insulin After 5 Weeks of Treatment, Skeletal muscle insulin sensitivity was measured as cGDR (referred to as delta RD \[basal vs high insulin\]) using a 2-step 5.5 hour euglycemic hyperinsulinemic clamp (EHC) procedure in combination with infusion of D-glucose (6,6-D2) glucose. Delta RD (basal vs high insulin) was corrected for urinary glucose excretion and measured at the end of Treatment Periods 1 and 2., At end (Week 5) of Treatment Periods 1 and 2 | Other: Change in Endogenous Glucose Production (EGP) After 5 Weeks of Treatment, A 2-step 5.5 hour EHC in combination with infusion of 6,6-D2 glucose was used to determine rates of EGP at the end of Treatment Periods 1 and 2. Results of the change in EGP are presented as delta EGP (basal vs low insulin and basal vs high insulin)., At end (Week 5) of Treatment Periods 1 and 2|Change in Respiratory Exchange Ratio (RER) From Fasted State to Insulin Stimulated State After 5 Weeks of Treatment, During the indirect calorimetry of the EHC test, respiratory gas exchange was measured using open air circuit respirometry with an automated ventilated hood system. Metabolic flexibility was determined by the change in RER from fasted state to insulin stimulated state at the end of Treatment Periods 1 and 2 and results are presented as delta RER (basal vs high insulin)., At end (Week 5) of Treatment Periods 1 and 2|24-Hour RER After 5 Weeks of Treatment, RER was measured before and after meals over a 24-hour period., At end (Week 5) of Treatment Periods 1 and 2|24-Hour Energy Expenditure After 5 Weeks of Treatment, Whole body energy expenditure was measured over a 24-hour period., At end (Week 5) of Treatment Periods 1 and 2|Body Composition (Fat Mass and Lean Mass) After 5 Weeks of Treatment, On Day 6, 7 or 8 of the end of treatment visit in both treatment periods, a Dual-energy X-ray absorptiometry (DEXA) scan was used to determine body composition., At end (Week 5) of Treatment Periods 1 and 2|Body Composition (Total Mass) After 5 Weeks of Treatment, On Day 6, 7 or 8 of the end of treatment visit in both treatment periods a DEXA scan was used to determine body composition., At end (Week 5) of Treatment Periods 1 and 2|Fibroblast Growth Factor 21 (FGF21) Area Under the Curve (AUC) in Plasma After 5 Weeks of Treatment, From the end of Day 1 until the morning of Day 3 of the end of each treatment visit, the patients stayed in the metabolic chamber (36 hours). During this stay FGF21 was measured in plasma before and after meals and before bed-time to determine the AUC (last 24 hours)., At end (Week 5) of Treatment Periods 1 and 2
|
